27
total announcements
524804.BO · 15 min delayed
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has informed the exchanges that the US FDA inspection at Unit-VI of Apitoria Pharma Private Limited, a wholly owned subsidiary, has concluded with three procedural observations. The company will respond to the US FDA within the stipulated timeline.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has announced the voting results of its 39th Annual General Meeting (AGM) held on August 27, 2026. All resolutions were approved by shareholders with a requisite majority. The company also announced the payment of an interim dividend of Rs.4/- per equity share.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd held its 39th Annual General Meeting (AGM) on August 27, 2026, through video conferencing. The meeting was attended by 86 members, and the requisite quorum was present. The Chairman, Mr. M.R. Kumar, conducted the proceedings and informed the members that the integrated Annual Report for the financial year 2025-26 was sent to them through electronic mode. The shareholders were also provided with the facility to cast their votes electronically through remote e-voting, and those present at the AGM were given an opportunity to cast their votes at the end of the meeting through poll (electronic).
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has announced its participation in an investor/analyst meet held on September 1-2, 2026 in Hong Kong. The meet is organized by Goldman Sachs Asia Leaders and will include one-on-one meetings and group meetings. The company's officials will be present to discuss the company's performance and future prospects. No unpublished price sensitive information (UPSI) is intended to be discussed during the interactions.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has announced an investor/analyst meet scheduled on September 1, 2026, where officials will participate in one-on-one and group meetings. The meeting schedule is subject to change due to exigency.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has informed that the US FDA conducted a routine inspection at its wholly-owned subsidiary Lannett Company LLC, a US-based pharmaceutical company, from August 17-21, 2026, and concluded with four procedural observations. The company will respond to the US FDA within the stipulated timeline and is committed to maintaining robust quality and compliance standards.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has completed a US FDA inspection at Auro Peptides Ltd, a subsidiary, with only one observation related to facility and equipment maintenance. The company has initiated corrective action and will submit a formal response within the stipulated timeline.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd's US FDA-inspected Raleigh Plant in North Carolina has been classified as Voluntary Action Indicated (VAI) after a 17-day inspection from March 24 to April 10, 2025, resulting in 11 observations. The company has received the Establishment Inspection Report (EIR) and can now progress with pending applications for multiple inhalers and other dosage forms.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has announced that its officials will participate in an investor and analyst meeting on August 19, 2026, at the Motilal Oswal 22nd Annual Global Investor Conference in Mumbai.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd's wholly owned subsidiary, Eugia Pharma Specialities Ltd, received a warning letter from the US FDA for its Unit I formulation manufacturing facility, which has an insignificant impact on the company's overall revenue.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has incorporated a new wholly owned subsidiary company, Auropharm Overseas Limited, to undertake manufacturing and marketing operations in India and foreign countries.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has submitted a notice to the stock exchanges regarding a special window for re-lodging transfer requests of physical shares, and TAAL Tech Limited has announced its unaudited consolidated financial results for the quarter ended June 30, 2026.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has submitted copies of newspaper advertisements of its financial results for the first quarter ended June 30, 2026, as published in Business Standard and Nava Telangana on August 7, 2026.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has announced that its officials will participate in an investor/analyst meet in Singapore and Hong Kong from August 11 to 13, 2026.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has announced the submission of copies of notice published in newspapers for the 39th Annual General Meeting (AGM) to be held on August 27, 2026. The notice was published in Business Standard and Nava Telangana on August 4, 2026, intimating shareholders about the dispatch of the notice of AGM, e-voting information, and book closure dates.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has sent a letter to shareholders who have not registered their email ids, providing a weblink for the integrated Annual Report 2025-26 and informing them about the 39th AGM to be held on August 27, 2026.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, as required by SEBI regulations.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has announced the notice of its 39th Annual General Meeting (AGM) to be held on August 27, 2026, through video conferencing. The AGM will consider and adopt the audited standalone and consolidated financial statements for the financial year ended March 31, 2026, and reappoint two directors, Mr. K. Nithyananda Reddy and Dr. M. Madan Mohan Reddy, who retire by rotation. The AGM will also consider the appointment of a secretarial auditor for a period of 5 years.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd submitted its Integrated Annual Report 2025-26, along with the Notice of 39th Annual General Meeting, to be held on August 27, 2026. The report covers the company's performance, strategic priorities, governance practices, and long-term value creation journey.
Aurobindo Pharma Ltd
Aurobindo Pharma Ltd has announced that its 39th Annual General Meeting will be held on August 27, 2026, through video conferencing or other audio-visual means.